U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Go back to U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 9.55 +0.01 (0.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.54 | 52 Week High | $19.40 | |||
| Open | $9.54 | 52 Week Low | $12.50 | |||
| Day High | $9.59 | P/E | N/A | |||
| Day Low | $9.53 | EPS | $0.00 | |||
| Volume | 452,047 | |||||
| Seattle Genetics Inc /wa (NASDAQ: SGEN) | Delayed: 228.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.74 | 52 Week High | $75.36 | |||
| Open | $228.74 | 52 Week Low | $26.02 | |||
| Day High | $228.74 | P/E | N/A | |||
| Day Low | $228.74 | EPS | $-0.51 | |||
| Volume | 1,668,682 | |||||
